Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports
Abstract Background The only pharmacologic prophylaxis against respiratory syncytial virus (RSV) infection in preterm infants is the humanized monoclonal antibody palivizumab. After the 2014 modification of the American Academy of Pediatrics (AAP) recommendations, the Italian Medicines Agency (AIFA)...
Saved in:
Main Authors: | Renato Cutrera (Author), Andrea Wolfler (Author), Simonetta Picone (Author), Giovanni A. Rossi (Author), Giuliana Gualberti (Author), Rocco Merolla (Author), Antonio Del Vecchio (Author), Alberto Villani (Author), Fabio Midulla (Author), Andrea Dotta (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2019-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
by: Antonino Capizzi, et al.
Published: (2017) -
Palivizumab prophylaxis of RSV infections in Bosnia and Herzegovina
by: Suada Heljic, et al.
Published: (2016) -
Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review
by: Marina Davoli, et al.
Published: (2021) -
Adolescent gender dysphoria management: position paper from the Italian Academy of Pediatrics, the Italian Society of Pediatrics, the Italian Society for Pediatric Endocrinology and Diabetes, the Italian Society of Adolescent Medicine and the Italian Society of Child and Adolescent Neuropsychiatry
by: Valeria Calcaterra, et al.
Published: (2024) -
Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective
by: Nusrat Homaira, et al.
Published: (2014)